Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Metrics to compare | PALI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPALIPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −3.1x | −0.6x | |
PEG Ratio | −0.01 | 0.03 | 0.00 | |
Price/Book | 2.6x | 2.5x | 2.6x | |
Price / LTM Sales | - | 147.3x | 3.3x | |
Upside (Analyst Target) | - | 156.2% | 37.9% | |
Fair Value Upside | Unlock | −5.1% | 3.7% | Unlock |